Flavone Acetic Acid in Human Melanoma
Author Information
Author(s): T.S. Maughan, R. Ward, I. Dennis, D.J. Honess, P. Workman, N.M. Bleehen
Primary Institution: University Department and MRC Unit of Clinical Oncology and Radiotherapeutics, Addenbrooke's Hospital
Hypothesis
The study investigates whether the lack of antitumor activity of flavone acetic acid (FAA) in human melanoma is due to reduced drug penetration compared to mouse tumors.
Conclusion
The study concludes that reduced penetration of FAA into human tumors is unlikely to explain the lack of antitumor activity observed in clinical studies.
Supporting Evidence
- FAA showed impressive effects against murine solid tumors but no activity in clinical studies.
- Mean tumor concentrations achieved in human melanoma were similar to those in mice.
- Reduced penetration of FAA into human tumors is unlikely to explain the lack of activity in clinical studies.
Takeaway
The researchers looked at how much of a drug called FAA gets into human melanoma tumors compared to mouse tumors, and found that the amount is similar, suggesting the drug might not work in humans for other reasons.
Methodology
The study involved a Phase II trial where patients with metastatic melanoma received FAA, and tumor biopsies were taken to measure drug concentrations.
Limitations
The study only included a small number of patients and had limited time points for measuring drug concentrations in human tumors.
Participant Demographics
Nine patients (six female, three male) aged 28-69 with metastatic melanoma were included.
Want to read the original?
Access the complete publication on the publisher's website